2'-Fucosyllactose (2'-FL) and 3-fucosyllactose (3-FL) are two fucosylated human milk oligosaccharides. They contain the same three simple sugars and share the same molecular formula and molecular weight, but they are still two different ingredients.
The difference lies in where fucose connects to lactose. In 2'-FL, fucose connects to galactose through an alpha-1,2 linkage. In 3-FL, fucose connects to glucose through an alpha-1,3 linkage. A linkage describes the position and direction of the bond between two sugar units.
Because their structures differ, 2'-FL and 3-FL have separate product identities, CAS numbers, applications, and regulatory references. Nutrition companies should not replace one with the other without reviewing the formula, evidence, specification, and destination-market requirements.
2'-FL usually provides the clearest starting point when a product concept needs an individual HMO with more human-study examples and an earlier U.S. GRAS history. 3-FL gives formulation teams another naturally occurring fucosylated structure and often appears in multi-HMO concepts. That does not mean 2'-FL is better than 3-FL. The suitable choice depends on the intended application, consumer group, evidence plan, and target market.
2'-FL and 3-FL at a Glance
| Point of Comparison | 2'-FL | 3-FL |
|---|---|---|
| Full Name | 2'-Fucosyllactose | 3-Fucosyllactose |
| HMO Family | Fucosylated HMO | Fucosylated HMO |
| Simple Sugars | Fucose, galactose, and glucose | Fucose, galactose, and glucose |
| Fucose Connection | Alpha-1,2 linkage to galactose | Alpha-1,3 linkage to glucose |
| CAS Number | CAS 41263-94-9 | CAS 41312-47-4 |
| Molecular Formula | C18H32O15 | C18H32O15 |
| Relative Molecular Mass | 488.44 | 488.44 |
| Our Current Target-HMO Specification | At least 94.0% on a water-free basis | At least 90.0% on a water-free basis |
| Our Current Water or Moisture Limit | No more than 5.0% water | No more than 9.0% moisture |
The specification values above describe our current 2'-FL and 3-FL products. They are not universal limits for every commercial source.
Molecular Identity
The Structural Difference in Plain Language
Both molecules begin with lactose, which contains glucose and galactose. Each molecule also contains one fucose unit. The point where that fucose unit attaches separates the two structures.
In 2'-FL, fucose connects to galactose through an alpha-1,2 linkage. In 3-FL, fucose connects to the glucose part of lactose through an alpha-1,3 linkage.
Chemists call 2'-FL and 3-FL structural isomers. Structural isomers contain the same types and numbers of atoms but arrange those atoms differently. That is why the two HMOs share a formula and molecular mass while keeping separate names, CAS numbers, analytical methods, and regulatory records.
The different linkage also matters to microorganisms. Bacterial enzymes often recognize one sugar connection more readily than another. In a laboratory system designed to simulate the infant colon, both 2'-FL and 3-FL affected bifidobacteria and microbial metabolites. Responses varied among the infant stool samples used to start the simulations. The 2'-FL and 3-FL colon-simulation study supports evaluating each HMO separately. It does not prove that either HMO produces a superior health effect in people.
Natural Levels Do Not Set a Universal Formula Amount
Both 2'-FL and 3-FL occur naturally in human milk, but their amounts vary widely. Maternal genetics, stage of lactation, location, and individual biology all affect the HMO profile.
2'-FL Weighted Mean
Grams per liter across the human-milk studies included in the analysis.
3-FL Weighted Mean
Grams per liter across the human-milk studies included in the analysis.
The authors also reported substantial variation among studies. These weighted human-milk concentration results describe observed milk samples; they do not establish a universal amount for infant formula, supplements, or other finished products.
The ratio between 2'-FL and 3-FL is not fixed either. One longitudinal study found that 3-FL concentration increased during the 24 months covered by the study, while 2'-FL did not show the same pattern. The longitudinal lactation study shows why natural occurrence can guide research but cannot replace a product-specific safety, regulatory, and evidence review.
Product Quality
How to Compare 2'-FL and 3-FL Specifications
Do not choose between 2'-FL and 3-FL by looking only at the headline purity percentage. A complete comparison must cover the assay basis, related carbohydrates, moisture, process-related limits, contaminants, and microbiological limits.
Water-Free Assay
Assay means the measured amount of the target HMO. A water-free assay removes the measured water from the purity calculation. It describes the target HMO relative to the dry part of the powder.
Our current 2'-FL specification sets at least 94.0% 2'-FL on a water-free basis. Our current 3-FL specification sets at least 90.0% 3-FL on the same basis. The 94.0% and 90.0% values do not, by themselves, show which HMO is more suitable for a finished product. The two specifications control different related carbohydrates and allow different moisture levels.
Related Carbohydrates
Related carbohydrates are sugars and oligosaccharides that may remain after fermentation and purification. Their identity depends on the target HMO and production process.
Our current 2'-FL specification limits D-lactose to 3.0% and difucosyllactose (DFL) to 2.0%. DFL is a related HMO containing two fucose units.
Our current 3-FL specification limits D-lactose to 3.0%, L-fucose to 3.0%, and the combined amount of D-galactose and D-glucose to 2.0%. These limits describe a different related-sugar profile from the 2'-FL specification.
| Specification Item | 2'-FL | 3-FL |
|---|---|---|
| Target HMO | 2'-FL, water-free basis: >=94.0% | 3-FL, water-free basis: >=90.0% |
| D-Lactose | <=3.0% | <=3.0% |
| Related Carbohydrates | Difucosyllactose: <=2.0% | L-Fucose: <=3.0%; D-galactose and D-glucose combined: <=2.0% |
| Water or Moisture | Water: <=5.0% | Moisture: <=9.0% |
| Ash | <=0.5% | <=0.5% |
| Residual Protein | <=100 mg/kg | <=100 mg/kg |
| Endotoxins | <=10 EU/mg | <=10 EU/mg |
| Lead | <=0.05 mg/kg | <=0.05 mg/kg |
| Total Plate Count | <=500 CFU/g | <=500 CFU/g |
| Enterobacteriaceae | <10 CFU/g | <10 CFU/g |
| Salmonella | Absent in 25 g | Absent in 25 g |
These release limits help formulation and quality teams compare the powders, but the finished-product category may require additional tests or tighter internal limits. Infant nutrition, medical nutrition, beverages, and supplements do not always use the same qualification plan.
Product Development
Application Decisions for Nutrition Companies
2'-FL and 3-FL can both support early-life and broader nutrition development where the applicable market rules permit the exact ingredient and use. Start with the finished product instead of assuming that two fucosylated HMOs are interchangeable.
Infant and Young-Child Nutrition
2'-FL has been studied as the single added HMO in infant formula. In one randomized controlled trial, researchers compared a formula containing 1.0 g/L 2'-FL and a defined probiotic strain with the same formula and probiotic without 2'-FL. The 2'-FL infant-formula trial reported age-appropriate growth and comparable tolerance between the formula groups. The result applies to the tested formula, 2'-FL amount, probiotic strain, and study population.
3-FL has also reached human infant research, but an important example uses a five-HMO blend rather than 3-FL alone. The tested formula contained 2'-FL, 3-FL, LNT, 3'-SL, and 6'-SL at a total HMO concentration of 5.75 g/L. The five-HMO growth and tolerance trial evaluated the complete formula and blend. Its results cannot be assigned to 3-FL alone.
This difference matters when a nutrition company builds an evidence file. A study of one HMO can support discussion of that tested HMO and formula. A blend study supports the tested blend. It does not identify how much each individual HMO contributed to the outcome.
Multi-HMO Formulas
Using both 2'-FL and 3-FL can add two different fucosylated structures to a multi-HMO formula. That structural variety may fit a concept designed around several HMO families or a blend used in published research.
The number of HMOs does not determine product quality. A useful blend needs a defined purpose, a permitted amount for every HMO, an evidence plan for the complete formula, compatible specifications, and analytical testing that measures each HMO separately.
Adult Nutrition, Supplements, and Specialized Products
FDA GRAS notices for 2'-FL and 3-FL include food and beverage categories beyond infant formula. Some notices also cover oral or enteral nutrition products. These records show possible commercial directions, but each notice applies to the ingredient source, food categories, age groups, and levels described in that notice.
Using the same HMO does not make infant-formula evidence, serving levels, or label claims suitable for an adult supplement. Product developers must evaluate the adult product's safety, serving amount, directions for use, and evidence for any claims.
Processing Fit
Processing and Stability
Both HMOs have useful stability data in food systems, but the final formulation still needs a pilot test under its actual process and storage conditions.
An EFSA safety assessment reported 3-FL stability in representative cereal bars, pasteurized juice, pasteurized and UHT milkshakes, and fruit yogurt under the tested processing and storage conditions. The same assessment also discussed data for high-purity 2'-FL and 3-FL standards in pasteurized whole milk, yogurt, and UHT milk. The EFSA 3-FL assessment provides useful formulation evidence for both fucosylated HMOs.
This evidence does not guarantee stability in every formula. Acidity, heat exposure, water activity, minerals, proteins, packaging, and storage time can change the result. A practical development program measures the HMO before processing, after processing, and at selected points during shelf life.
Evidence Review
How the Research Evidence Differs
Nutrition companies should separate four questions when reviewing 2'-FL and 3-FL:
- Has the exact HMO been studied by itself or only as part of a blend?
- Did the study involve people, animals, cells, or a laboratory model of the gut?
- Did the study test the same consumer group and finished-product format?
- Does the result support safety and tolerance, a biological observation, or a finished-product claim?
Published human studies include more examples in which 2'-FL was the single added HMO. The 3-FL examples cited in this guide use a laboratory system or a multi-HMO formula. For a 3-FL project, do not present a 2'-FL study as direct proof for 3-FL. For a blend project, do not present the result as proof that one component produced the complete effect.
Market Review
U.S. FDA References: Compare Notices, Not Just Use Levels
In the United States, GRAS means Generally Recognized as Safe for the intended uses described in a specific safety conclusion. FDA may respond that it has no questions about the notice. That response is not an approval of every source, use, dosage, label, or health claim for an HMO.
The 2'-FL GRN 650 record lists term infant formula at up to 2.4 g/L and several foods and drinks at category-specific amounts. FDA closed this notice in 2016 with a no-questions letter.
The 3-FL GRN 1099 record lists term infant formula at up to 0.9 g/L, formula for children aged 1 to 3 years at up to 1.2 g/L, and category-specific amounts for other foods, drinks, and oral or enteral formulas. FDA closed this notice in 2023 with a no-questions letter.
The 2.4 g/L and 0.9 g/L values come from different notices for different ingredient sources. They are not competing recommended dosages, and they do not show that a higher amount produces a better result. A nutrition company must match its exact ingredient source and finished-product category with the appropriate safety conclusion.
Our HMO use-level and regulatory database provides a broader starting point for all six HMO types. Always open the current FDA record before finalizing a U.S. formulation.
European Union References: Confirm the Exact Source
The European Union authorizes HMOs through the novel food system. The relevant entry can define the production source, specification, permitted food categories, maximum levels, labeling conditions, and temporary data-protection rights.
Regulation (EU) 2024/2036 added a fermentation-derived 2'-FL source to the Union List under the currently authorized conditions of use. The regulation also gives the named applicant temporary protection for supporting data related to that source.
Regulation (EU) 2023/52 added a defined fermentation-derived 3-FL source, along with its conditions of use, labeling requirements, specification, and data-protection period.
These regulations show why a nutrition company must check more than the short name "2'-FL" or "3-FL." The commercial ingredient must match an applicable Union List entry or another valid authorization path. The HMO name alone does not confirm that a particular manufacturing source can enter the EU market.
Project Checklist
A Practical Selection Checklist
- Who will use the finished product: infants, young children, adults, or a specialized nutrition group?
- Where will the finished product be sold?
- Is the finished product an infant formula, supplement, powder, beverage, food, or oral or enteral formula?
- Does the evidence plan require 2'-FL by itself, 3-FL, or a defined multi-HMO blend?
- Does the current market record cover the exact HMO source, category, consumer group, and proposed amount?
- Are the assay basis and related-carbohydrate limits suitable for the formula and quality plan?
- Can the analytical method measure 2'-FL and 3-FL separately in the finished product?
- Has a pilot batch confirmed solubility, processing stability, sensory fit, and shelf-life performance?
- Do the proposed label and claims match the evidence and destination-market rules?
We manufacture fermentation-derived 2'-FL and 3-FL for nutrition product development. We help nutrition companies compare the two HMO types, discuss the intended application, review the current specification, arrange samples, and plan a suitable starting point for formulation trials.
Review our 2'-FL product page, 3-FL product page, or contact us about an HMO project.